Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

General Practice Research Database Seroquel XR Safety Study

Completed

Conditions: Major Depressive Disorder
Bipolar Disorder
Schizophrenia

First Posted Date: 2011-10-05

Last Posted Date: 2014-02-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 37372

Registration Number: NCT01447082

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland

Badalona Major Depressive Disorder Database Study

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2011-10-05

Last Posted Date: 2012-01-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 2260

Registration Number: NCT01446692

Locations: 🇪🇸
Research Site, Badalona, Spain

AZD2115 Multiple Ascending Dose Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: AZD2115
Drug: Placebo

First Posted Date: 2011-10-04

Last Posted Date: 2012-10-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 32

Registration Number: NCT01445782

Locations: 🇬🇧
Research Site, London, UK, United Kingdom

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

Phase 4

Completed

Conditions: COPD
Respiratory Disorders
Pulmonary Disease
Lung Diseases
Chronic Obstructive Lung Diseases
COPD Exacerbation
Chronic Obstructive Airway Disease

Interventions: Drug: Roflumilast
Drug: Placebo

First Posted Date: 2011-09-30

Last Posted Date: 2017-04-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 2354

Registration Number: NCT01443845

Locations: 🇷🇺
Forest Investigative Site 612, St. Petersburg, Russian Federation
🇷🇺
Forest Investigative Site 600, St Petersburg, Russian Federation
🇺🇸
Forest Investigative Site 248, Baltimore, Maryland, United States

and more 335 locations

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: budesonide pMDI
Drug: Symbicort pMDI

First Posted Date: 2011-09-30

Last Posted Date: 2016-12-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 12460

Registration Number: NCT01444430

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

Phase 1

Completed

Conditions: Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin

Interventions: Drug: Onglyza (saxagliptin)
Drug: 5-mg saxagliptin/500 mg metformin
Drug: Diabex
Drug: 5-mg saxagliptin/1000 mg metformin

First Posted Date: 2011-09-28

Last Posted Date: 2012-02-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 28

Registration Number: NCT01441869

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate
Drug: Formoterol Fumarate

First Posted Date: 2011-09-21

Last Posted Date: 2017-05-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 590

Registration Number: NCT01437540

Locations: 🇺🇸
Forest Investigative Site 1927, Los Angeles, California, United States
🇺🇸
Forest Investigative Site 1851, Atlanta, Georgia, United States
🇺🇸
Forest Investigative Site 1567, Atlanta, Georgia, United States

and more 134 locations

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Formoterol Fumarate
Drug: Aclidinium Bromide/Formoterol Fumarate
Drug: Aclidinium Bromide
Drug: Placebo

First Posted Date: 2011-09-20

Last Posted Date: 2017-03-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 1692

Registration Number: NCT01437397

Locations: 🇺🇸
Forest Investigative Site 1900, Atlanta, Georgia, United States
🇺🇸
Forest Investigative Site 1570, Fall River, Massachusetts, United States
🇺🇸
Forest Investigative Site 1587, Chesterfield, Missouri, United States

and more 219 locations

Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation

Completed

Conditions: Gastric Ulcer
Lymphoma Idiopathic Thrombocytopenic Purpura
Duodenal Ulcer
Gastric Mucosa-associated Lymphoid Tissue (MALT)
Early Gastric Cancer

First Posted Date: 2011-09-16

Last Posted Date: 2014-04-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 369

Registration Number: NCT01435525

Locations: 🇯🇵
Research Site, Yamanashi, Japan

Nexium Capsules Clinical Experience Investigation

Completed

Conditions: Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome

First Posted Date: 2011-09-15

Last Posted Date: 2014-04-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 3691

Registration Number: NCT01434485

Locations: 🇯🇵
Research Site, Yamanashi, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy